Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia

Open access
Frey, Noelle V., Gill, Saar, Hexner, Elizabeth O., Schuster, Stephen, Nasta, Sunita, Loren, Alison, Svoboda, Jakub, Stadtmauer, Edward, Landsburg, Daniel J., Mato, Anthony, Levine, Bruce L., Lacey, Simon F., Melenhorst, Jan Joseph, Veloso, Elizabeth, Gaymon, Avery, Pequignot, Edward, Shan, Xinhe, Hwang, Wei-Ting, June, Carl H., Porter, David L.·2020·Journal of Clinical Oncology

Abstract

PURPOSE: To describe long-term outcomes of anti-CD19 chimeric antigen receptor T (CART) cells in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). METHODS: Between January 2013 and June 2016, 42 patients with relapsed or refractory CLL were enrolled in this study and 38 were infused with anti-CD19 CART cells (CART-19). Of these, 28 patients were initially randomly assigned to receive a low (5 × 10 7) or high (5 × 10 8) dose of CART-19, and 24 were evaluable for response assessment. After an interim analysis, 10 additional patients received the selected (high) dose and of these, eight were evaluable for response. Patients were followed for a median 31.5 months (range, 2 to 75 months). RESULTS: At 4 weeks, the complete and overall responses for the 32 evaluable patients were 28% (90% CI, 16% to 44%) and 44% (90% CI, 29% to 60%), respectively. The median overall survival (OS) for all patients was 64 months; there was no statistically significant difference between low- and high-dose groups ( P = .84). Regardless of dose, prolonged survival was observed in patients who achieved a CR versus those who did not ( P = .035), with median OS not reached in patients with CR versus 64 months in those without CR. The median progression-free survival was 40.2 months in patients with CR and 1 month in those without a CR ( P < .0001). Toxicity was comparable in both dose groups. CONCLUSION: In patients with advanced CLL, a 5 × 10 8 dose of CART-19 may be more effective than 5 × 10 7 CART-19 at inducing CR without excessive toxicity. Attainment of a CR after CART-19 infusion, regardless of cell dose, is associated with longer OS and progression-free survival in patients with relapsed CLL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.03237

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 179

Metadata

Authors
Frey, N. V., Gill, S., Hexner, E. O., Schuster, S., Nasta, S., Loren, A., Svoboda, J., Stadtmauer, E., Landsburg, D. J., Mato, A., Levine, B. L., Lacey, S. F., Melenhorst, J. J., Veloso, E., Gaymon, A., Pequignot, E., Shan, X., Hwang, W.-T., June, C. H., & Porter, D. L.
Venue
Journal of Clinical Oncology
Published
2020-09-01
Volume
38
Issue
25
Pages
2862-2871
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3016273290
Cited by
179
References
3
FWCI
8.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. https://app.cochat.ai/papers/10.1200/jco.19.03237
The paper
Frey, N. V., Gill, S., Hexner, E. O., Schuster, S., Nasta, S., Loren, A., Svoboda, J., Stadtmauer, E., Landsburg, D. J., Mato, A., Levine, B. L., Lacey, S. F., Melenhorst, J. J., Veloso, E., Gaymon, A., Pequignot, E., Shan, X., Hwang, W.-T., June, C. H., & Porter, D. L. (2020). Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.03237

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.